Investigational drug · Phase 2
AVM0703
Also called: Supra-Pharmacologic Dexamethasone Phosphate
Not approved by FDA. In 1 industry-sponsored Phase 2 or 3 trial that is active or finished in the last two years, most often for Lymphoid Malignancies.
Phase 2Last checked: Nov 19, 2026Latest source record: Apr 15, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
1
1 still active
All registered trials
3
Any phase or sponsor naming "AVM0703"
First trial start
2020
Nov 6, 2020
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "AVM0703", any sponsor or status.
Conditions studied
As listed on its trial records.
- Lymphoid Malignancies
Largest trials
Live from ClinicalTrials.gov: studies naming "AVM0703" as an intervention, largest first.
AVM Biotechnology IncIndustry
NCT04329728 · 144 participants (planned) · Start Nov 6, 2020 · Primary completion Nov 30, 2027
Drug: AVM0703 · For: Lymphoid Malignancies
Sites: Duarte, California; Los Angeles, California; Whittier, California · 11 sites in all
- Evaluating AVM0703 for Treatment of COVID-19 or Influenza-mediated ARDSNot yet recruiting
AVM Biotechnology IncIndustry
NCT04366115 · 16 participants (planned) · Start Dec 1, 2026 · Primary completion Dec 1, 2031
Drug: AVM0703; Placebo · For: ARDS; Covid19; Influenza, Human
AVM Biotechnology IncIndustry
NCT05974410
Drug: AVM0703; Hydrocortisone and 1 more · For: Glioblastoma; Squamous Cell Carcinoma; Hodgkin Lymphoma and 14 more
Newest research
PubMed records naming it or its code names, newest first.
No PubMed records name it yet, which is common for early code-named drugs.
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.